Offer comparable efficacy to
insulin
insulin
For
your patients
<<
BYETTA InfoSite Home
When a sulfonylurea was used, the incidence of hypoglycemia was similar
between the insulin glargine + sulfonylurea group (n = 58) and the BYETTA
+ sulfonylurea group
(n = 60) (34.5% vs 30%, respectively).*[1]
No increased risk of hypoglycemia when BYETTA was used in combination with
metformin.
BYETTA delivered weight loss while insulin glargine led to
Offer comparable efficacy to insulin
BYETTA® delivered similar A1C reductions as insulin glargine
BYETTA showed significantly less hypoglycemia than insulin glargine
When a sulfonylurea was used, the incidence of hypoglycemia was similar
between the insulin glargine + sulfonylurea group (n = 58) and the BYETTA
+ sulfonylurea group(n = 60) (34.5% vs 30%, respectively).*[1]
No increased risk of hypoglycemia when BYETTA was used in combination with
metformin.*Results compared the addition of BYETTA or insulin
glargine to current therapy of metformin or a sulfonylurea in a randomized,
2-period, open-label, crossover clinical trial (n = 114). Patients in
the BYETTA group received 5 mcg BID for 4 weeks and 10 mcg BID thereafter
for a total of
16 weeks. Patients in the insulin glargine group received QD subcutaneous injections titrated as needed to reach a target fasting blood glucose of
≤100 mg/dL (5.6 mmol/L). The treatment regimens were then switched for an additional 16 weeks, so by the end of the study all patients had received
16 weeks of BYETTA therapy and 16 weeks of insulin glargine therapy. Hypoglycemia was defined as patient-perceived signs or symptoms, with or without glucose <60 mg/dL.
16 weeks. Patients in the insulin glargine group received QD subcutaneous injections titrated as needed to reach a target fasting blood glucose of
≤100 mg/dL (5.6 mmol/L). The treatment regimens were then switched for an additional 16 weeks, so by the end of the study all patients had received
16 weeks of BYETTA therapy and 16 weeks of insulin glargine therapy. Hypoglycemia was defined as patient-perceived signs or symptoms, with or without glucose <60 mg/dL.
BYETTA is not a substitute for insulin in insulin-requiring patients.
Offer a secondary benefit of weight loss…
BYETTA delivered weight loss while insulin glargine led to
weight gain
*Results compared the addition of BYETTA or insulin
glargine to current therapy of metformin or a sulfonylurea in a randomized,
2-period, open-label, crossover clinical trial (n = 114). Patients in
the BYETTA group received 5 mcg BID for 4 weeks and 10 mcg BID thereafter
for a total of
16 weeks. Patients in the insulin glargine group received QD subcutaneous injections titrated as needed to reach a target fasting blood glucose of
≤100 mg/dL (5.6 mmol/L). The treatment regimens were then switched for an additional 16 weeks, so by the end of the study all patients had received
16 weeks of BYETTA therapy and 16 weeks of insulin glargine therapy.
16 weeks. Patients in the insulin glargine group received QD subcutaneous injections titrated as needed to reach a target fasting blood glucose of
≤100 mg/dL (5.6 mmol/L). The treatment regimens were then switched for an additional 16 weeks, so by the end of the study all patients had received
16 weeks of BYETTA therapy and 16 weeks of insulin glargine therapy.
